Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson's Disease (PD). The Company expects the following milestones for the dalzanemdor (SAGE-718) Phase 2 clinical development program in 2024: Mid-2024: Report topline data from SURVEYOR Study in people with HD cognitive impairment; Late 2024: Report topline data of LIGHTWAVE Study in people with MCI and mild dementia in AD; Report topline data from DIMENSION Study in people with HD cognitive impaired.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.01 USD | +2.56% | -2.67% | -44.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.58% | 723M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.38% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease